-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
-
LUNGevity: Lung Cancer’s Warrior in the Fight Against Misinformation
Online health content often contains harmful information. Worse, research shows inaccurate data may attract more attention than evidence-based information.
-
In Brief for February 23, 2022
TTLC 2022 gets under way. WCLC registration now open but abstract submission deadline is coming soon.
-
Regulatory News for February 23, 2022
Taiwan OKs nivolumab IV infusion in some cases. UK approves atezolizumab for NSCLC. European Commission greenlights lorlatinib for advanced ALK-positive disease.
-
Association of Race with Lung Cancer Risk Among Adults Undergoing Lung Cancer Screening
Data suggest lung cancer risk scores are not aligned with lung cancer diagnoses in Black patients. Take a closer look at how race influences lung cancer screening.
-
The Art and Science of Patient–Doctor Communication: Part 2
In the second half of our series on patient-doctor communication, see how medical students are learning the skills they need to better communicate with patients.
-
Ongoing Research Looks at Optimizing Lung Cancer Screening Programs
Studies seek to optimize lung screening by monitoring incidentally detected nodules, delaying some repeat scans, and balancing false positives against delayed diagnosis.
-
GO2 Foundation for Lung Cancer Aims to Create Resources for Caregivers
A new survey provides a voice for caregivers regarding the challenges they face and rewards they gain from lung cancer co-survivorship.
-
In Brief for February 9, 2022
TTLC goes virtual. Positive results reported for pembrolizumab. GO2 Foundation names Chief of Healthcare Delivery.
-
Regulatory News for February 9, 2022
Sotorasib earns approval in European Union, Japan. Scotland OKs osimertinib.
-
Introducing the New ILCN
As we embark on a third year of practice and research during an ever-evolving, seemingly ceaseless pandemic, we know there will be more changes and challenges in store for the field of thoracic oncology. We welcome the rapid deployment of scientific advances and are grateful for how these advances have expanded our treatment options and…